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ABSTRACT 
Exposure to replication competent lentivirus (RCL) is a theoretical safety concern for individuals 
treated with lentiviral gene therapy. For certain ex vivo gene therapy applications, including 
cancer immunotherapy trials, RCL detection assays are used to screen the vector product as well 
as the vector-transduced cells. In this study, we reviewed T cell products screened for RCL using 
methodology developed in the National Gene Vector Biorepository. All trials utilized third 
generation lentiviral vectors produced by transient transfection. Samples from 26 clinical trials 
totaling 460 transduced cell products from 375 subjects were evaluated. All cell products were 
negative for RCL. A total of 296 of the clinical trial participants were screened for RCL at least 1 
month after infusion of the cell product. No research subject has shown evidence of RCL 
infection. These findings provide further evidence attesting to the safety of third generation 
lentiviral vectors and that testing T cell products for RCL does not provide added value to 
screening the lentiviral vector product.   
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INTRODUCTION 
Adoptive therapy with genetically modified T cells using lentiviral vectors is in advanced 
stages of clinical development for cancer indications by academic investigators and several 
companies.1-4 Commercial approval by the US Food and Drug Administration of CTL019, a 
CD19 CAR T cell for the therapy of relapsed leukemia is expected in 2017.  In addition, several 
centers are testing engineered hematopoietic stem cells and other targets using gene transfer with 
lentiviral vector technology.5-9 Thus, detection of replication competent lentivirus (RCL) is 
emerging as a major issue given the widespread use of lentiviral vector technology.  
Detecting RCL in lentiviral vector products is a key release test to ensure patients are not 
inadvertently exposed to replicating virus. The most likely source of RCL virus would be 
recombination between vector sequences and the viral genes expressed during vector 
manufacture.10-12 Detection of a vector-associated RCL is challenging given this virus is still 
theoretical and therefore the components of the virus are unknown. Replicating viruses have 
been described in the manufacture of vectors based on murine leukemia viruses (MLV). Most 
commonly, these MLV-derived viruses arose through recombination of vector and packaging 
sequences and decreasing homology between vector and packaging sequences has been shown to 
decrease virus formation.13-22 Some recombinant retroviruses have also been shown to contain 
vector packaging sequences and cellular derived genes.23, 24 This raises the possibility that a RCL 
could contain packaging sequences along with endogenous human retroviral25 or other cellular 
components. This experience with MLV-based vectors has shaped FDA recommendations for 
recombinant virus testing, including recommendations for RCL assays.26  
In the US, a lentiviral vector lot must be screened for RCL prior to clinical use.27 
Research subjects are also continuously monitored after treatment for the presence of RCL. A 
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third assessment is also required for any cell product cultured ex vivo for more than 4 days, since 
a putative RCL that was not detected in the vector release assay may be amplified in cell culture 
and thus become detectable. As the majority of T cell receptor (TCR) and chimeric antigen 
receptor (CAR) vector trials use cell expansion, RCL screening of the infused T cell product is 
required for most cancer immunotherapy trials. This requirement presents challenges to the 
clinical development of T cell applications due to the number of cells that must be tested (1% of 
the cell product or 108 cells, whichever is less),27, 28 the complexity of assessing RCL in high titer 
vector,29 and the associated expense of screening this large number of cells.   
RCL detection is also complicated by the similarity between vector and viral particles. 
Many components of an RCL will be similar to a vector particle (capsid, integrase and reverse 
transcriptase) so most protein detection methods will not be fruitful. Similarly, assay for reverse 
transcriptase activity30, 31 cannot distinguish RCL from vector particles. While vector genomes 
lack genes used in viral replication, these genes must be expressed in vector producing cells and 
any carryover of cellular or plasmid DNA into the vector product can lead to false positive 
molecular assays. Moreover, all non-culture assays to date lack the sensitivity of culture based 
assays where theoretically one infectious unit can be amplified to large numbers.11 A number of 
RCL culture assays have been described including syncytia formation assays capable of 
detecting a fully competent lentivirus but the sensitivity of this approach in detecting an 
attenuated virus has not been extensively studied.32 Marker rescue assays have also been 
described for HIV-1 but whether a RCL arising from vector production will mobilize the marker 
is unknown.33, 34 To date, the most common assays for screening gene therapy products are 
assays which combine an amplification phase using a cell line capable of expanding attenuated 
viruses to high titer, with subsequent detection of virus using ELISA or molecular assays. 29, 35-39  
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Since RCL arising during vector production are still theoretical, their growth rate is 
unknown, but it is likely to be significantly attenuated compared to wild type lentiviruses due to 
the absence of accessory genes.33 Therefore, regulators have required biologic assays to utilize 
an extended culture period of approximately 3 weeks (a minimum of 5 passages)27 to amplify 
any slow growing viruses. Using this stringent screening method, RCL has not been reported in 
any research or clinical lentiviral vector preparations. The lack of RCL provides support for the 
overall safety of lentiviral vectors and suggests the multiple safety features incorporated in 
vector design are effective in limiting RCL development.40  
 Since the advent of lentiviral vectors for clinical application in 2003, a conservative RCL 
testing approach has been implemented to allow for an optimal risk:benefit for patients, while the 
field gathered experience with this new vector system.  It is unknown whether the testing of 
infused products adds additional value to the testing of the vector product. In this paper, we 
review the experience of the National Gene Vector Biorepository (NGVB), a NHLBI funded 
resource to assist investigators in meeting FDA requirements for gene therapy 
(www.NGVBCC.org). The NGVB has assisted investigators in testing T cell products for RCL 
from a variety of clinical trials. To date, none of the products tested were found to contain RCL. 
The data suggests that RCL testing of infused products does not provide additional assurances of 
safety and that screening vector products is a sufficient release test for third generation lentiviral 
vectors.  
 
RESULTS 
Lentiviral vectors have much in common with native lentiviruses making it difficult to 
distinguish vector particles from RCL. Biologic assays which expose permissive cell lines to 
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vector preparations have been shown to be the preferred method of RCL detection.11, 35, 36  In 
2011, we reported our assay’s methodology and performance in testing clinical vector products.29 
The general components of the RCL assay used in this study are shown in Figure 1. Test articles 
and parallel positive and negative controls are added to C8166-45 T cells and the cultures 
maintained for three weeks (amplification phase). C8166-45 T cells have been shown to generate 
HIV-1 to high titer and also show high transduction with VSV-G (Vesicular Stomatitis Virus – 
G) pseudotyped vector.11, 35 Culture supernatant is then used to inoculate naïve C8166-45 cells 
which are cultured for an additional week. Cultures are then screened for RCL using two 
methods: (1) p24 ELISA for HIV capsid protein and, (2) a molecular based assay (either psi-gag 
PCR11 or Product Enhanced Reverse Transcriptase,30 PERT). As the true nature of a RCL 
remains theoretical, we chose two methods of virus detection to improve the chance of 
identifying an unusual recombinant. 
T cell product analysis. This analysis reviewed RCL testing of cellular products from 
June 2011 until August of 2016. All investigators who submitted greater than 10 test articles to 
the NGVB were invited to participate, all agreed to submit data. The test articles represent 97.9% 
of T cell products tested within this time period. Table 1 summarizes the general characteristics 
of the 26 research studies. All trials utilized a third generation lentiviral vector,41 4 studies 
involved TCR vector while 17 utilized CAR vectors. The trials utilized vectors to transduce T 
cell populations or T cell subset populations. All vector utilized in clinical trials were determined 
to be RCL negative by the manufacturer.  
Table 2 provides information about RCL testing. A total of 499 assays were performed 
during the study period. The T cell manufacturing processes for initial studies included a parallel 
non-transduced control, which provided an opportunity to evaluate assay performance for false 
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positives. After 39 assays of non-transduced control samples were analyzed and found to be RCL 
negative, the NGVL requested investigators limit subsequent sample submission to transduced 
cell products only. A total of 460 transduced cell products are included in this analysis. All were 
RCL negative. The number of T cells within a product varied per protocol. The US FDA requires 
1% of the cell product (up to 1 x 108 cells) be screened for RCL and over half of products tested 
contained or approached the 1 x 108 maximum. Clinical trials with lower numbers were those 
treating pediatric subjects or transducing T cell subsets. The total number of transduced cells 
tested from all studies was 2.4 x 1010.   
 Subject Follow-up.  Not all products screened for RCL were infused into the intended 
research subject due to non-RCL related issues. As shown in Table 3, of the 460 transduced 
products tested for RCL, 409 were infused (89%). A number of trials utilized multiple products 
per subject, with the 409 products infused into 375 subjects. To help provide additional 
validation of the RCL testing method, subjects who underwent RCL testing at time points >30 
days post-infusion were tabulated and listed in Table 2. A total of 296 of the 375 (79%) subjects 
had a least one RCL test performed after infusion, all analyzes were negative for RCL. In all but 
one subject, RCL detection of peripheral blood was performed using a PCR for VSV-G envelope 
DNA.  
Assay Performance.  The RCL assay used in this paper is composed of two culture 
phases, an initial amplification phase and a second indicator phase. Culture media is tested at the 
end of the amplification phase for HIV capsid protein (p24 ELISA). Media from the indicator 
phase is tested for HIV capsid protein as well as a molecular based assay (psi-gag PCR or 
PERT). Due to the large number of cells per test articles, over half of the assays contained only 2 
test articles per assay. Successful performance of the amplification phase is critical since failure 
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to complete this portion of the assay requires resubmission of test articles and significantly 
delays test completion. Reviewing the 499 RCL test articles analyzed, there were 13 out of 
specifications or deviations noted in the amplification phase. Repeat testing was justified by 
prospective assay acceptance criteria or following a corrective and preventative action plan and 
applied to 11 samples. Defective culture flasks caused loss of cells in 2 test articles; both test 
articles contained 1 x 108 cells which were split among 25 flasks. Investigators indicated that the 
remaining 9.6 x 107 was sufficient to meet the 1% FDA testing requirement and the assay was 
completed without requiring additional test articles. For 2 test articles in one assay, the 
amplification phase positive controls where negative requiring resubmission of test articles. Two 
additional amplification phases cultures were lost due to technician error. In 3 test articles from 
two different investigators, the test articles inhibited the growth of the C8166-45 cells. 
Resubmitted test articles also showed inhibition and the assay was completed by increasing the 
number of C8166-45 cells at each passage. All resubmitted test articles discussed above 
completed the assay successfully and were found to be negative for RCL at the amplification and 
indicator phase. During review of all assays for this analysis, 2 assays were found to have a 
miscalculation in the number of C8166-45 cells added to the culture; the ratio of test article cell 
to C8166-45 was 1:4.35 which is below the minimum of 1:5 specified for this assay.  
There were 8 indicator phase assays that failed to meet acceptability criteria. Three of the 
assays failed due to technician error. One indicator phase culture grew slowly, and repeat using 
reserve material also showed slow growth of C8166-45 cells; sufficient cells were available for 
analysis. Four indicator assays were repeated because the positive controls were negative. 
Reserve amplification phase media was available for all the indicator phase assays noted above; 
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resubmission test articles were therefore not needed. All indicator phases cultures using reserve 
amplification phase media were found to be negative for RCL.  
Amplification and Indicator Phase culture media is subjected to p24 ELISA analysis to 
identify HIV capsid protein, a predicted component of any RCL. Each test article and control is 
run in duplicate wells. There were no instances when both duplicate wells were positive, which 
is an acceptance criterion for a positive assay. There were 15 instances when one well was below 
and one slightly above the limits of detection; 9 occurred in a test article and 6 in a negative 
control samples. In all cases, repeat analysis with reserve material found the sample to be below 
the limits of detection (12.5 pg/mL). In addition, the test articles in question were negative by 
psi-gag PCR or PERT. All test articles tested by ELISA met the criteria for RCL negative 
samples.  
Between June 2011 and March of 2013, 84 test articles were analyzed by the psi-gag 
PCR assay. One assay did not meet criteria due to a positive signal detected in both the test 
article and the negative control. The p24 ELISA result for this test article was negative in both 
the amplification and indicator phase. The assay was repeated and both negative control and test 
article were negative, test article was considered negative for RCL. After March of 2013, the 
PERT assay replaced psi-gag PCR. There were 3 PERT assays where the standard curve did not 
meet acceptability criteria and 1 assay where the positive control did not meet acceptance 
criteria. The assays were repeated using reserve material and met acceptance criteria. In 
analyzing 417 test articles by PERT, there were 4 test articles and 2 negative control test articles 
which were just above baseline. The corresponding p24 analysis was negative and repeat PERT 
testing using reserve samples was negative for reverse transcriptase. Upon retesting, all test 
articles met the criteria for RCL negative samples.     
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DISCUSSION 
Inadvertent exposure of subjects to pathogens that contaminate gene therapy products is a 
top safety concern. Lentiviral vectors have been designed to minimize the chance of 
recombination and, to date, RCL has not been detected in research materials generated with third 
generation vector systems. In 2011, we also showed that 16 lentiviral vector products 
manufactured for clinical trial use had no evidence of RCL.29 Continued testing at the NGVB has 
failed to detect RCL using material submitted from a variety of manufacturing facilities. In this 
manuscript, we provide further evidence for the biosafety of lentiviral vector production systems. 
Using a sensitive RCL assay, there was no evidence of replicating virus in 460 T cell products. 
The products tested span 26 clinical trials at 6 different institutions. Follow-up analysis of treated 
research subjects also found no evidence of RCL. Given the lack of documented RCL in a large 
number of T cell products, the design features of third generation lentiviral vectors, and the lack 
of documented RCL in clinical vector lots, RCL testing of T cell products does not appear to 
provide additional assurances of safety and testing requirements should be re-evaluated. Our 
findings also have implications for research laboratories and suggest re-evaluation of biosafety 
requirements for third generation lentiviral vectors.   
In developing a detection assay for RCL, we developed an assay that was exhaustive by 
intent. The assay uses both p24 ELISA and a molecular detection assay (psi-gag PCR or PERT) 
to provide redundancy in order to minimize false positive or false negative results due to 
technical error. Since we do not know the components of a RCL, two assays aimed at different 
components of the RCL may also increase the chance of RCL detection. For example, a RCL 
containing endogenous human retroviral or other unpredicted sequences may not be recognized 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 11 
in assays aimed at detecting HIV-1. The addition of the indicator phase also ensures that the 
assay detects a true RCL by requiring passage from amplification phase cells to naïve C8166-45 
cells. The assay has been validated to detect 1 IU of RCL per 106 test article cells, and in this 
study, there was a total of 2.4 x 1010 transduced T cells tested. 
The design of third generation lentiviral vectors suggest the risk of RCL is significantly 
lower than that of MLV-based vectors.40 The ability to segregate the vector components onto 
four plasmids, the use of self-inactivating (SIN) LTR’s, and retention of Rev dependence all 
contributes to the safety profile of lentiviral vectors.41, 42 HIV-1 also depends on a number of 
accessory genes and regulatory sequences that are deleted in lentiviral vector systems, further 
limiting the growth potential of any RCL. Furthermore, lentiviral vectors are generally produced 
by transient transfection which limits the time for recombination events. Whether the experience 
in vector products generated by transient transfection will extend to lentiviral packaging cell 
lines awaits further studies. The most current lentiviral lines do suppress gene expression until 
shortly before vector harvest and also incorporate many of the safety features described above.43, 
44
 This predicts a significantly greater safety profile than the MLV-based packaging cell lines but 
additional experience is required to establish whether these will consistently generate RCL-free 
vector products.  Similarly, the propensity for RCL development in HIV-1 based vectors with 
significant differences in vector design, method of manufacture, or envelope will require 
bridging or full validation studies. Also, our findings do not extend to non-HIV-1 based 
lentiviruses or other retroviral vector systems. 
In general, the RCL assay described here performed well. Of the 499 test articles 
analyzed there were 11 test articles that required resubmission due to technical issues. Three of 
the 11 required resubmission due to growth inhibition of the C8166-45 cells. Growth inhibition 
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appeared to be related to the cellular product; there were no apparent issues of microbial 
contamination, samples were run on different assays, and were obtained from different 
investigators, and there was no evidence of p24 in the amplification phase media. The assays 
were repeated and increasing the number of cells at each split allowed the assays to be 
completed. Interestingly, the three products in questions (representing 3 of 499 products test or 
0.6%) were CD4 T cell subset samples.  
There were occasions when a single replicate well in p24 or PERT was above 
background will all other analyses for p24 and PERT were negative. This occurred in test articles 
and negative controls. Given the greater number of test articles run per assays compared to the 
negative control, there is no evidence of a higher frequency occurring in test articles. Both p24 
ELISA and PERT assays are performed in plates, the most likely cause of the sporadic positive 
wells is aerosolization of positive control materials during set up and handling of the plates. 
In addition to testing the T cell products, we collected data from the 26 clinical trials on 
post-infusion RCL testing. The US FDA requires subjects infused with lentiviral transduced 
products be monitored for RCL but currently there is no guidance requiring a specific assay. 
Interestingly, each investigator independently chose qPCR for the VSV-G envelope as the 
preferred method for RCL monitoring. To date, no evidence of VSV-G envelope DNA has been 
reported in the subjects enrolled in the 26 clinical trials surveyed.  
In summary, RCL has not been detected in third generation lentiviral vector products 
manufactured for clinical use.29 We now add to that experience by analyzing T cell products used 
in cancer immunotherapy. In 460 products tested, using a vigorous biologic assay for RCL, there 
was no evidence of RCL. Participants evaluated post-infusion of T cell products were also 
without evidence of RCL exposure. These findings suggest that current vector design and vector 
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product screening provide a high level of assurance regarding the absence of replicating virus. 
Therefore, screening T cell products for RCL does not add additional assurance of safety and 
should no longer be required when the lentiviral vector product has been successfully screened 
for RCL.  
 
MATERIALS AND METHODS 
Collection of Study Data.  The NGVB is a National Heart, Lung and Blood Institute 
sponsored resource that assist gene therapy investigators in meeting FDA required testing 
(www.NGVBCC.org) and all T cell product testing was performed centrally at the NGVB. For 
this study, RCL assays performed between June 2011 and August 2016 were reviewed and all 
investigators with at least one study of greater than 10 subjects were invited to participate. Only 
samples intended for in vivo administration were included in the analysis.  Investigators agreeing 
to participate were sent a list of their studies along with the test articles name and the dates of 
assay initiation and completion. Participants were asked to supply the following information (1) 
lentiviral vector type (second or third generation); (2) target cell type; (3) transgene type (TCR, 
CAR, other); (4) if the product was administered to the subject; (5) the clinical vector product 
was shown to be RCL free prior to use in the clinical trial; and (6) if the subject was screened for 
RCL at > 30 days after product administration. For subjects screened for RCL after product 
administration, the testing was not done centrally and the method of screening was at the 
investigators discretion. All were screened by VSV-G except for one patient tested by serology 
in a clinical pathology laboratory for HIV-1 p24 antigen.  
Cell Line and Positive Control Preparation. The C8166-45 (derived from human 
umbilical cord lymphocytes) cell line was obtained from the AIDS Research and Reference 
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Reagent Program (Rockville, MD) and HEK293T cells were obtained from the American Type 
Culture Collection (Manassas, VA). The former was maintained in RPMI 1640 media while the 
latter were maintained in Dulbecco’s modified Eagle medium (DMEM). Both media were 
obtained from Invitrogen, Carlsbad, CA and supplemented with 10 % fetal calf serum (FCS; 
Hyclone, Logan, UT), 2 mM L-glutamine (Invitrogen), and 100 units/ml penicillin and 100 
µg/ml streptomycin (Invitrogen)), (RPMI10 and D10 respectively). D10 also contains sodium 
pyruvate 100 mM and L-glutamine 200 mM. C8166-45 cells are maintained in cell banks and 
only those cells at < 15 passages at the start of an assay are utilized. The attenuated HIV-1 
positive control is generated by transfecting HEK293T cells with the pR8.71 plasmid (provided 
from Cell Genesys, 112 µg plasmid per 5x 106 cells/) followed by a media change at 24 hours. 
Cell free supernatant (0.45 µm filter) is collected 48 hours after transfection. Material is stored at 
< -70o C then thawed for potency assessment by preparing thirty nine 50-mL flat bottom culture 
tube with 1 x 106 C8166-45 cells per tube and incubating cells overnight. On day 0, 6 tubes are 
centrifuged and cells are resuspended in 1 mL of virus with Polybrene at 8 µg/mL. The six 
dilutions tested range from 10-3 to 10-8 of the frozen viral stock. Three negative control tubes are 
also prepared. After a 4-hour incubation, cells are pelleted, resuspended in RPMI, and transferred 
to 6-well plates. Cells are maintained in log-phase growth for at 12 days after which time cells 
are pelleted, and the media is filtered (0.45 µm) and assessed for p24 by ELISA. Cultures are 
read as positive or negative based on the lower limits of detection of the ELISA assay (12.5 
pg/mL).  
RCL Assays.  Amplification Phase. The RCL assay used here has previously been 
reported for screening lentiviral vector products29 and was used with the modifications described 
in the text below. Control triplicate negative and positive control cultures are prepared on day – 1 
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by adding 12 mL of RPMI10 and 5 X 106 C8166-45 cells into six 50 mL culture tubes (flat-
bottom 10-cm2). Test article flasks are prepared on day -1 based on the number of cells to be 
tested. A minimum of 1 test cell to 5 C8166-45 is required for the assay. Most investigators 
submit 108 cells which require twenty five 300 cm2 flasks. On Day 0, the negative control culture 
media is replaced with 1 mL of RPMI10 and Polybrene (8 µg/mL) and the three positive controls 
are inoculated with 1 mL of RPMI10, 5 IU of R8.71 virus, and 8 µg/mL Polybrene. On day 0 the 
test article cells are introduced into the flasks containing C8166-45 cells. After four hours, 
cultures are centrifuged and media replace with RPMI10. Cells are passed for 3 weeks with a 
minimum of 5 splits. Cultures in larger flasks are split into decreasing size flasks with cells 
cultured in 75 cm2 flasks by the end of week 3. The media is not conducive for primary T cell 
growth and C8166-45 cell predominate at the end of the amplification phase.  
Indicator Phase. At the end of the 3 week culture, test article and negative and positive 
control culture cells are resuspended in fresh RPMI10 and media is collected after 24 hours then 
filtered (0.45 µm). Naïve C8166-45 cells (1 x 106 C8166-45 cells in 4 mL) are incubated 
overnight then cultured with the filtered media for 4 hours in the presence of Polybrene (8 
µg/mL). For a test article, the material from all flasks are pooled and used to inoculate 2 test 
article indicator phase flasks. After 6 days in cultures, cells are resuspended in fresh media and 
collected 24 hours later, filtered (0.45 µm) and analyzed for evidence of RCL. All samples in this 
paper were assessed for RCL using the p24 ELISA assay, a commercially available kit (Alliance 
HIV-1 p24 ELISA kit, Perkin Elmer, Waltham, MA) as previously described.29 All 
measurements were done in duplicate. For test articles, any value above the limits of detection 
(12.5 pg/mL) is considered positive. For the positive controls, values above the upper limits of 
detection (100 pg/mL) are expected.  
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The psi-gag PCR assays detects recombinants between the psi and gag viral genes and is 
described in Sastry et al.11 with a modification to include a second PCR for human beta globin to 
validate that the test article DNA is of sufficient quantity and quality. The psi-gag PCR assay 
required PCR amplification followed by Southern blot analysis with a P32-labeled probes and 
added significant time to the assay turnaround. A validation study was performed demonstrating 
equivalency of the PERT assay30 to the psi-gag PCR assay, samples after March 2013 were 
evaluated by PERT. The limits of detection in the PERT assay is 100 RT molecules per 25 uL; 
positive controls at the end of the indicator phase are expect to be in excess of 104 RT molecules 
per 25 uL.  
Acceptance criteria is defined as follows. At the end of the indicator phase, the assay is 
acceptable if (1) all 3 negative controls are negative for p24 antigen; (2) all 3 negative controls 
are negative for psi-gag sequences or PERT; (3) at least one of the positive controls flasks are 
positive for p24 antigen and psi-gag at the indicator phases. If the controls are acceptable and the 
2 test article flasks are negative for p24 antigen and psi-gag PCR/PERT then the test article is 
reported as negative for RCL. If the test article is positive for both p24 and psi-gag, the sample is 
interpreted as RCL positive. If both test article flasks are positive in one assay but negative in the 
other (ex. positive for p24 and negative for psi-gag PCR/PERT), the indicator phase is repeated 
and extended for > 14 days before samples are harvested and tested. If one of two test article 
flasks are positive in one assay and negative in the other assay then both assays are repeated with 
reserve samples (ex. one flask above and one below background in the ELISA assay and both 
flasks negative in psi-gag PCR/PERT). The only time the indicator phase is not repeated is when 
one of the 10 test article analyses is above background (each test article has 2 flasks from the 
indicator phase, each flask is tested in duplicate for 24 and in triplicate by PERT for a total of 10 
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analyses per test article). In this case, the discrepant sample is retested from reserve material 
from the initial indicator phase. If the repeat testing is negative, the sample is considered 
negative for RCL.    
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FIGURE LEGENDS 
 
Figure 1. Schematic representation of the RCL Assay. T cell products are incubated with C8166-
45 cells at a ratio of 1:5. Over half of test articles submitted contained approximately 1 x 108 T 
cells and were divided into twenty five 300 cm2 flasks. Cultures are passed a minimum of 5 
passaged using increasingly smaller vessels. After 3 weeks, cells are placed in fresh media and 
conditioned media is harvested after 24 hours. Media from all amplification cultures are pooled 
and two aliquots are then incubated with naïve C8166-45 cells. After 7 days, culture media is 
analyzed for p24 antigen by ELISA and either the psi-gag PCR assay or PERT. The figure 
depicts amplification of a low titer RCL present in the test article.  
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Table 1. Clinical Protocols Submitting Transduced T Cell Products for Replication Competent 
Lentivirus Testing.  
 
Study 
Number Clinical Trial # 
Principle 
Investigator 
Initial  
Assay 
Initiated 
Final  
Assay 
Completed 
Vector 
Generation 
Transgene 
class 
Transduced 
Cell Type 
11-2 NCT01350401  June 8/8/11 10/28/13 Third TCR T cell 
11-3 NCT01352286  June 6/27/11 4/15/13 Third TCR T cell 
11-4 NCT01343043  June 12/6/12 2/13/13 Third TCR T cell 
11-11 NCT01626495 June 7/11/12 2/20/14 Third CAR-T T cell 
11-12 NCT01029366 June 12/15/11 9/9/13 Third CA -T T cell 
11-13 NCT01551043 June 12/15/11 12/15/11 Third CAR-T T cell 
12-4 NCT01626495 June 7/2/14 11/9/16 Third CAR-T T cell 
12-16 NCT01683279 Jensen 12/8/14 3/16/15 Third CAR-T CD4, CD8 
13-4 NCT01747486 June 3/21/13 4/18/16 Third CAR-T T cell 
13-12 
NCT01567891, 
NCT01352286, 
NCT01350401, 
NCT01343043 
Binder-
Scholl 9/5/15 3/9/16 Third TCR T cell 
13-15 
NCT01318317, 
NCT01815749 Forman 2/13/14 2/13/14 Third CAR-T memory T 
14-9 NCT02030847 June 4/2/14 8/4/16 Third CAR-T T cell 
14-10 NCT02030834 June 5/5/14 5/2/16 Third CAR-T T cell 
14-12 NCT01865617 Turtle 5/28/14 8/24/15 Third CAR-T CD4, CD8 
14-18 NCT02315612 Fry 1/26/15 6/13/16 Third CAR-T T cell 
14-27 NCT01815749 Forman 2/12/15 2/12/15 Third CAR-T memory T 
15-9 NCT02146924a Forman 3/30/14 10/26/15 Third CAR-T memory T 
15-10 NCT02153580 Forman 3/30/15 10/26/15 Third CAR-T memory T 
15-11 NCT02051257 Forman 3/30/15 10/26/15 Third CAR-T memory T 
15-26 NCT02028455 Jensen 12/8/14 3/18/16 Third CAR-T CD4, CD8 
15-36 NCT02208362 Forman 10/26/15 10/26/15 Third CAR-T memory T 
16-1 NCT02311621 Jensen 4/4/16 6/17/16 Third CAR-T CD4, CD8 
a  1 patient treated on a compassionate use basis linked to this study; TCR = T cell receptor; 
CAR-T = chimeric antigen receptor T cell; T = T cell. 
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Table 2. Number of RCL Assays Performed by Study and the Number of Cell Analyzed. 
 
Study 
Number 
Principle 
Investigator 
# 
Samples 
Assayed 
# 
negative 
control 
samples 
# 
transduced 
samples 
Total 
number 
of control 
cells 
tested 
Total 
number of 
transduced 
cells tests 
Average 
number of 
transduced 
cells per 
assay 
Median 
number of 
cells per 
assay 
11-2 June 5 2 3 2.00E+08 3.00E+08 1.00E+08 1.00E+08 
11-3 June 43 20 23 1.88E+09 2.05E+09 8.90E+07 1.00E+08 
11-4 June 4 2 2 2.00E+08 2.00E+08 1.00E+08 1.00E+08 
11-11 June 33 5 28 4.07E+08 2.24E+09 7.98E+07 1.00E+08 
11-12 June 27 9 18 4.11E+08 1.27E+09 7.04E+07 9.80E+07 
11-13 June 2 1 1 5.00E+07 5.00E+07 5.00E+07 5.00E+07 
12-4 June 41 0 41 0 3.20E+09 7.80E+07 1.00E+08 
12-16 Jensen 3 0 3 0 8.75E+07 2.92E+07 3.07E+07 
13-4 June 35 0 35 0 2.64E+09 7.53E+07 8.73E+07 
13-12 Binder-Scholl 36 0 36 0 3.60E+09 1.00E+08 1.00E+08 
13-15 Forman 6 0 6 0 9.60E+07 1.60E+07 1.65E+07 
14-9 June 30 0 30 0 2.39E+09 8.11E+07 1.00E+08 
14-10 June 39 0 39 0 3.25E+09 8.33E+07 1.00E+08 
14-12 Turtle 90 0 90 0 1.73E+09 1.92E+07 2.00E+07 
14-18 Fry 14 0 14 0 1.20E+08 8.57E+06 1.00E+07 
14-27 Forman 7 0 7 0 5.09E+07 7.26E+06 5.80E+06 
15-9 Forman 6 0 6 0 3.00E+07 5.00E+06 4.38E+06 
15-10 Forman 6 0 6 0 3.63E+07 6.04E+06 3.13E+06 
15-11 Forman 11 0 11 0 1.14E+08 1.03E+07 1.00E+07 
15-26 Jensen 45 0 45 0 3.65E+08 8.30E+06 7.50E+06 
15-36 Forman 2 0 2 0 5.75E+06 2.88E+06 2.88E+06 
16-1 Jensen 14 0 14 0 1.49E+08 1.06E+06 1.00E+07 
TOTAL   499 39 460 3.15E+09 2.40E+10 
MEAN       4.64E+07 5.26E+07 
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Table 3. Follow-up Testing for Replication Competent Lentivirus (RCL) in Subjects Infused with Gene Modified T Cell Products.  
IU VPF Study 
Number 
Principle 
Investigator 
# Products 
Infused 
# Subjects 
Infused 
# Subjects with 
RCL Follow-up* 
Method of RCL 
Detection 
Level of Sensitivity 
per DNA 
11-2 June 2 2 1 VSV-G DNA PCR 25 copies per 1 ug 
11-3 June 19 17 16 VSV-G DNA PCR 25 copies per 1 ug 
11-4 June 2 2 2 VSV-G DNA PCR 25 copies per 1 ug 
11-11 June 24 24 21 VSV-G DNA PCR 25 copies per 1 ug 
11-12 June 14 13 13 VSV-G DNA PCR 25 copies per 1 ug 
11-13 June 1 1 0 VSV-G DNA PCR 25 copies per 1 ug 
12-4 June 36 36 34 VSV-G DNA PCR 25 copies per 1 ug 
12-16 Jensen 3 3 2 VSV-G DNA PCR 10 copies per 50ng 
13-4 June 32 32 23 VSV-G DNA PCR 25 copies per 1 ug 
13-12 Binder-Scholl 31 31 24 VSV-G DNA PCR 5 copies per 100 ng 
13-15 Forman 5 5 5 VSV-G DNA PCR 2.5 copes per 50 ng 
14-9 June 25 25 14 VSV-G DNA PCR 25 copies per 1 ug 
14-10 June 34 34 30 VSV-G DNA PCR 25 copies per 1 ug 
14-12 Turtle 76 76 49 VSV-G DNA PCR 10 copies per 1 ug 
14-18 Fry 14 14 11 VSV-G DNA PCR 10 copies per 200 ng 
14-27 Forman 7 7 6 VSV-G DNA PCR 2.5 copes per 50 ng 
15-9 Forman 6 4 3** VSV-G DNA PCR 2.5 copes per 50 ng 
15-10 Forman 6 6 5 VSV-G DNA PCR 2.5 copes per 50 ng 
15-11 Forman 11 11 11 VSV-G DNA PCR 2.5 copes per 50 ng 
15-26 Jensen 45 23 19 VSV-G DNA PCR 10 copies per 50ng 
15-36 Forman 2 2 2 VSV-G DNA PCR 2.5 copes per 50 ng 
16-1 Jensen 14 7 5 VSV-G DNA PCR 10 copies per 50ng 
TOTAL 409 375 293   
* >  30 days post infusion; ** 2 subjects tested by PCR, 1 subject tested by serology 
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The safety of lentiviral vectors is a factor in their acceptance as clinical therapies. In this 
issue of Molecular Therapy, Cornetta et al. (2017) screened 460 cell products for 
replication competent lentivirus (RCL); none were positive. The low risk of RCL 
suggests revisions to US FDA testing guidelines are warranted.  
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